Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. 2008 Exclusive Survey—Earnings: Good news for primary care income 5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Top Ten Searches
post partum incontinence fibroid hpv colpotomy ovarian cyst curettage endometriosis intrauterine umbilical cordYour Article Summary
Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment
Clinical Interventions in Aging, 09/09/09
Derman R et al. – Postmenopausal women with GI irritability with daily or weekly BPs experienced improvement in symptoms with extended dosing monthly or quarterly ibandronate compared with baseline.
Methods- Two open–label trials: PRIOR and CURRENT.
- In PRIOR, women who had discontinued daily or weekly BP treatment due to GI intolerance received monthly oral or quarterly IV ibandronate for 12 months.
- The CURRENT subanalysis included women receiving weekly BP treatment who switched to monthly oral ibandronate for six months.
- GI symptom severity and frequency were assessed using the Osteoporosis Patient Satisfaction Questionnaire.
- In PRIOR, mean GI tolerability scores increased significantly at month 1 from screening for both treatment groups.
- Most patients reported improvement in GI symptom severity and frequency from baseline at all post–screening assessments (>90% at Month 10).
- In the CURRENT subanalysis >60% of patients reported improvements in heartburn or acid reflux and >70% indicated improvement in other stomach upset at month 6.
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
A New Drug in a New Class for Postmenopausal Osteoporosis
The Female Patient, 11/11/09
Systematic Review: Comparative Effectiveness of Medications to Reduce Risk for Primary Breast Cancer
Annals of Internal Medicine, 11/17/09
Effect of Transdermal Teriparatide Administration on Bone Mineral Density in Postmenopausal Women
Journal of Clinical Endocrinology and Metabolism, 11/10/09
Today in Menopausal Medicine...keeping you current
Receive free subspecialty "5-minute updates" via email
A New Drug in a New Class for Postmenopausal Osteoporosis
The Female Patient, 11/11/09
Effect of Transdermal Teriparatide Administration on Bone Mineral Density in Postmenopausal Women
Journal of Clinical Endocrinology and Metabolism, 11/10/09
Reducing hip fracture risk with risedronate in elderly women with established osteoporosis
Clinical Interventions in Aging, 11/11/09
Sponsor
Article Search
Sponsor


See Latest Articles


